NBC Securities Inc. Boosts Stake in Grifols, S.A. (NASDAQ:GRFS)

NBC Securities Inc. grew its holdings in Grifols, S.A. (NASDAQ:GRFS - Free Report) by 112,543.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 57,448 shares of the biotechnology company's stock after purchasing an additional 57,397 shares during the quarter. NBC Securities Inc.'s holdings in Grifols were worth $408,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Versant Capital Management Inc acquired a new stake in shares of Grifols in the first quarter valued at approximately $28,000. Blue Trust Inc. increased its stake in shares of Grifols by 254.0% in the 4th quarter. Blue Trust Inc. now owns 6,927 shares of the biotechnology company's stock worth $52,000 after acquiring an additional 4,970 shares during the last quarter. Tower Research Capital LLC TRC increased its stake in shares of Grifols by 354.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,124 shares of the biotechnology company's stock worth $60,000 after acquiring an additional 6,335 shares during the last quarter. First Trust Advisors LP purchased a new position in shares of Grifols during the 4th quarter worth $75,000. Finally, Envestnet Portfolio Solutions Inc. acquired a new position in shares of Grifols during the 4th quarter valued at about $77,000.

Grifols Trading Up 0.1%

GRFS stock traded up $0.01 during midday trading on Monday, hitting $8.83. 350,555 shares of the company's stock were exchanged, compared to its average volume of 1,162,295. Grifols, S.A. has a 1-year low of $5.79 and a 1-year high of $9.96. The company has a current ratio of 2.26, a quick ratio of 0.79 and a debt-to-equity ratio of 1.11. The stock has a market capitalization of $6.07 billion, a PE ratio of 7.55 and a beta of 0.53. The business has a 50-day simple moving average of $7.48 and a two-hundred day simple moving average of $7.53.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Wall Street Zen upgraded shares of Grifols from a "hold" rating to a "buy" rating in a research report on Friday, May 23rd. Morgan Stanley initiated coverage on shares of Grifols in a research note on Wednesday, February 12th. They issued an "overweight" rating for the company.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.